Literature DB >> 22045667

Pentoxifylline for steatohepatitis: magic bullet or smoking gun?

Richard K Sterling, Arun J Sanyal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22045667      PMCID： PMC4902103          DOI： 10.1002/hep.24612

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  43 in total

1.  Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.

Authors:  J E Lavine
Journal:  J Pediatr       Date:  2000-06       Impact factor: 4.406

Review 2.  Epidemiology of nonalcoholic fatty liver.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Clin Liver Dis       Date:  2004-08       Impact factor: 6.126

3.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

Review 4.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

5.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

6.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

7.  Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.

Authors:  Eva Lonn; Salim Yusuf; Byrcon Hoogwerf; Janice Pogue; Qilong Yi; Bernard Zinman; Jackie Bosch; Gilles Dagenais; Johannes F E Mann; Hertzel C Gerstein
Journal:  Diabetes Care       Date:  2002-11       Impact factor: 19.112

8.  Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.

Authors:  Claudia O Zein; Lisa M Yerian; Prema Gogate; Rocio Lopez; John P Kirwan; Ariel E Feldstein; Arthur J McCullough
Journal:  Hepatology       Date:  2011-08-24       Impact factor: 17.425

9.  Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.

Authors:  Vlad Ratziu; Fréderic Charlotte; Carole Bernhardt; Philippe Giral; Marine Halbron; Gilles Lenaour; Agnès Hartmann-Heurtier; Eric Bruckert; Thierry Poynard
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

10.  Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests.

Authors:  Marta I Minervini; Kristine Ruppert; Paulo Fontes; Riccardo Volpes; Giovanni Vizzini; Michael E de Vera; Salvatore Gruttadauria; Roberto Miraglia; Loredana Pipitone; J Wallis Marsh; Amadeo Marcos; Bruno Gridelli; Anthony J Demetris
Journal:  J Hepatol       Date:  2008-12-29       Impact factor: 25.083
View more
  2 in total

1.  Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study.

Authors:  Itziar Abete; M Angeles Zulet; Nuria Perez-Diaz-Del-Campo; Bertha Araceli Marin-Alejandre; Irene Cantero; J Ignacio Monreal; Mariana Elorz; José Ignacio Herrero; Alberto Benito-Boillos; Jose I Riezu-Boj; Fermín I Milagro; Josep A Tur; J Alfredo Martinez
Journal:  Eur J Nutr       Date:  2021-01-20       Impact factor: 5.614

Review 2.  Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease.

Authors:  Benoit Smeuninx; Ebru Boslem; Mark A Febbraio
Journal:  Cancers (Basel)       Date:  2020-06-28       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.